Vividion CMO Sales Trigger: Pipeline Alert
Vividion taps Sam Whiting as CMO. Late-stage trial gaps open. Pitch global CRO & R&D analytics. Boost your pipeline and commission.
Published on
Do not index
Do not index
🚀 Battle Card: Vividion Therapeutics, Inc.
This Vividion Therapeutics, Inc. sales trigger highlights a CMO hire at a pivotal clinical expansion moment.
Quick trigger:
👤 Decision Maker in the News
- Sam Whiting, M.D., Ph.D., Chief Medical Officer · 🔗 LinkedIn
💡 Why It Matters
- A seasoned oncology leader joins to sharpen trial design and accelerate pipeline momentum. → Source
🎯 Core Pain Point
- Lack of internal expertise in late-stage global clinical trials
- Scaling a complex small-molecule pipeline with limited bench-to-bedside data integration
💰 What to Pitch
- Primary: Global CRO partnership for oncology trials → streamlined execution and compliance
- Expansion: Integrated R&D data analytics platform → accelerated target validation and portfolio insights
🗺️ Quick Context
- HQ: San Diego, CA
- Employees: ≈ 200
- Rev: ≈ $30 M
- Website: https://vividion.com/
🤼 Competitive Intel
Which other vendors you’ll probably face to win Vividion Therapeutics, Inc.’s business.
- IQVIA — CRO / Clinical trial management
- Unique edge: global scale and oncology expertise
- Evaluated by CMO & VP Clinical Ops for trial execution
- Parexel — CRO / Clinical development
- Unique edge: regulatory consulting bundled
- Evaluated by Medical Affairs for compliance support
- Veeva Systems — R&D data platform
- Unique edge: unified clinical and regulatory cloud
- Evaluated by Head of R&D for data integration
✅ Do-Now Checklist
Connect with decision maker on LinkedIn (link above)
Send first-touch using Copy-My-Prompt block (Step 7)
Log Vividion Therapeutics, Inc. sales trigger in CRM and schedule follow-ups (Day 3 & Day 10)
Next Step
Get this Vividion Therapeutics, Inc. sales trigger daily—no fluff, all pipeline.
Subscribe to NewsletterForLeads for more Vividion Therapeutics, Inc. sales trigger intel.
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑❑
OFFER_BRIEF = ❑❑
PROOF_METRIC = ❑❑
CTA_STYLE = ❑❑
TONE = ❑❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Sam
COMPANY = Vividion Therapeutics, Inc.
DEPT = Medical
SIZE = ≈ TBD
BOTTLENECK = lack of internal expertise in late-stage global clinical trials
EVENT = Appointment of CMO
DETAIL = Appointment of Sam Whiting as CMO
PAIN = Scaling a complex small-molecule pipeline with limited bench-to-bedside data integration
SRC = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20250813751175&div=41152219
SIM_CO = Tempest Therapeutics
WIN_METRIC = 25% faster trial initiation
NEXT_SIZE = ≈ 300
EMP_EST = ≈ 200
REV_EST = ≈ $30M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: ≈ TBD-person Medical
Sam—noticed your Medical team is ≈ TBD.
That’s when lack of internal expertise in late-stage global clinical trials slows growth.
We helped Tempest Therapeutics fix this with Global CRO partnership for oncology trials.
Result: 25% faster trial initiation.
Quick call?
PS—next bottleneck hits ≈ 300.
DM ≤45 words, TONE:
Saw your post about Appointment of Sam Whiting as CMO — Scaling a complex small-molecule pipeline with limited bench-to-bedside data integration.
Global CRO partnership for oncology trials. 20% reduction in trial cycle time.
Quick chat?